Citations

Clear

2 citation(s) found for "Schneider, Amy".

Variants in ATP6V0C are associated with Dravet‐like developmental and epileptic encephalopathy
Rong, Marlene , Marques, Paula , Ali, Quratulain Zulfiqar , Morcos, Ricardo , Chandran, Ilakkiah , Qaiser, Farah , Møller, Rikke S. , Bayat, Allan , Rubboli, Guido , Gardella, Elena , Reuter, Miriam S. , Sands, Tristan T. , Scheffer, Ingrid E. , Schneider, Amy , Nabbout, Rima , Sullivan, Joseph , Valente, Kette D. , Brunklaus, Andreas , Marques, Paula T , Poduri, Annapurna , Wirrell, Elaine C , Nabbout, Rima , Sullivan, Joseph , Valente, Kette , Auvin, Stéphane , Knupp, Kelly G , Brunklaus, Andreas , Aledo-Serrano, Ángel , Andrade, Danielle M , Rubboli, Guido , Scheffer, Ingrid E , Gardella, Elena , Møller, Rikke S , Bayat, Allan , Wirrell, Elaine , Auvin, Stéphane , Knupp, Kelly G. , Andrade, Danielle M.

Mayo Clinic

Epilepsia | March 14, 2025 | Volume: 66 | Issue: 6 | Pages: 2046-2052

10.1111/epi.18346 | PMID 40085430 Get It

Abstract Objective Dravet syndrome (DS) is a developmental and epileptic encephalopathy. Diagnosis is clinical, but ~90% of patients have pathogenic variants in SCN1A . ATP6V0C has recently been proposed as a novel candidate gene for epilepsy, with or without developmental delay. Here we describe two adult patients with a clinical diagnosis of DS associated with ATP6V0C variants. Methods Patients with developmental and epileptic encephalopathies were evaluated by physicians who are experts in DS, and their clinical diagnosis was correlated with genetic findings. A subgroup of those patients with DS but without known genetic causes were evaluated through gene panels, whole exome sequencing, and chromosome microarray. Phenotype was determined by pediatric and adult chart reviews, interviews, and physical examinations. Results Of 753 patients with DS, two unrelated individuals with classic features of DS during childhood and adulthood were identified with heterozygous de novo missense variants in ATP6V0C (c.319G > C, p.(Gly107Arg) and c.284C > T, p.(Ala95Val), respectively). Both variants were absent in normal populations and computational prediction algorithms suggested deleterious effects on protein structure and/or function. No disease‐causing variants in other genes previously associated with DS were found. Significance Here we describe two adult patients with Dravet‐like syndrome and pathogenic/likely pathogenic variants in ATP6V0C . We propose that abnormal ATP6V0C function can, at the severe end of the clinical spectrum, be associated with Dravet‐like phenotype. This is relevant, as these patients would not qualify for disease‐modifying antisense nucleotide or gene therapies targeting SCN1A .
Neoadjuvant platinum-based chemotherapy and lymphadenectomy for penile cancer: an international, multi-institutional, real-world study
Pham, Rachel, Zacharias, Niki M. , Ionescu, Filip , Paravathaneni, Mahati, Marchetti, Kathryn , Sanchez, Darren , Mustasam, Arfa, Sandstrom, Reagan, Vikram, Raghu , Schneider, Amy, Pagliaro, Lance C. , Alifrangis, Constantine , Master, Viraj A. , Hernandez, Cindy, Moses, Kelvin A. , Protzel, Chris, Montgomery, Jeffrey S., Ángel, Martín , Tobias‐Machado, Marcos , Pettaway, Curtis A. , Chahoud, Jad , Nazha, Bassel , Chahoud, Jad , Rose, Kyle , Dhillon, Jasreman , Rao, Priya , Albersen, Maarten , Roussel, Eduard , Nazha, Bassel , Spiess, Philippe E.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | February 17, 2024 | Volume: 116 | Issue: 6 | Pages: 966-973

10.1093/jnci/djae034 | PMID 38366627 Get It

Abstract Introduction This study investigated the efficacy and safety of neoadjuvant chemotherapy for locally advance penile squamous cell carcinoma for which current evidence is lacking. Methods Included patients had locally advanced penile squamous cell carcinoma with clinical lymph node metastasis treated with at least 1 dose of neoadjuvant chemotherapy prior to planned consolidative lymphadenectomy. Objective response rates were assessed using Response Evaluation Criteria in Solid Tumors v1.1. The primary and secondary outcomes were overall survival and progression-free survival, estimated by the Kaplan–Meier method. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events v5.0. Results A total of 209 patients received neoadjuvant chemotherapy for locally advanced and clinically node-positive penile squamous cell carcinoma. The study population consisted of 7% of patients with stage II disease, 48% with stage III, and 45% with stage IV. Grade 2 treatment-related adverse events occurred in 35 (17%) patients, and no treatment-related mortality was observed. Of the patients, 201 (97%) completed planned consolidative lymphadenectomy. During follow-up, 106 (52.7%) patients expired, with a median overall survival of 37.0 months (95% confidence interval [CI] = 23.8 to 50.1 months) and median progression-free survival of 26.0 months (95% CI = 11.7 to 40.2 months). Objective response rate was 57.2%, with 87 (43.2%) having partial response and 28 (13.9%) having a complete response. Patients with objective response to neoadjuvant chemotherapy had a longer median overall survival (73.0 vs 17.0 months, P < .01) compared with those who did not. The lymph node pathologic complete response rate was 24.8% in the cohort. Conclusion Neoadjuvant chemotherapy with lymphadenectomy for locally advanced penile squamous cell carcinoma is well tolerated and active to reduce the disease burden and improve long-term survival outcomes.